Sage Journals: Discover world-class research

Abstract

Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are chronic inflammatory disorders of the upper airways with rising global prevalence, contributing significantly to health and socioeconomic burdens. Conventional treatments—including glucocorticoids, antibiotics, antihistamines, and leukotriene inhibitors—remain insufficient in targeting the underlying pathophysiology. Bacterial lysates (BLs), functioning as immunomodulators, activate both innate, and adaptive immune pathways, reestablish Th1/Th2 equilibrium, lower immunoglobulin E concentrations, and attenuate Th2-mediated inflammation. Emerging evidence indicates that BLs (e.g. OM-85, Broncho-Vaxom) markedly improve total nasal symptom scores in AR, suppress Th2 cytokine (IL-4 and IL-13) secretion, and reduce recurrence rates and surgical interventions in CRS. In conjunction with standard therapies, BLs enhance mucosal immune defense and contribute to sustained clinical efficacy. Following the Scale for the Assessment of Narrative Review Articles guidelines, this review critically evaluates the composition, manufacturing processes, immunoregulatory mechanisms, and clinical progress of BLs in AR and CRS, providing a conceptual framework for their clinical application.

Keywords

Bacterial lysates allergic rhinitis chronic rhinosinusitis immunomodulation

Introduction

Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are prevalent chronic inflammatory conditions of the upper airways frequently encountered in clinical settings. Over recent decades, global prevalence rates have risen markedly. European data reveal an increase in AR prevalence among Danish adults from 19% to 32% over the past 30 years.¹ In China, a 2018 cross-sectional study in Wuhan reported a 28.6% AR prevalence among children aged 6–12 years,² nearly triple the 9.8% reported in 2005.³ Notably, self-reported rates of pollen-induced AR in northern grassland regions reached 32.4%.⁴ In Japan, three national surveys conducted between 2005 and 2015 documented a continuous rise in pediatric AR prevalence.⁵ Similarly, the burden of CRS is significant worldwide: prevalence estimates include 10.9% in Europe,⁶ 12–14% in the United States,⁷ 6.95% in South Korea,⁸ 5.51% in São Paulo, Brazil,⁹ and 8.0%—equating to 107 million individuals—in China.¹⁰ These widespread prevalence rates exert profound public health and economic impacts. For instance, annual treatment costs per patient with AR in the Netherlands amount to €4,827,¹¹ while Chinese patients with CRS demonstrate a 4.5-fold increase in healthcare utilization and an average of 11.7 days of work absenteeism annually compared to non-CRS individuals,¹² emphasizing the urgency of targeted interventions.¹³

Pathophysiologically, AR is characterized by chronic, non-infectious inflammation of the nasal mucosa, predominantly driven by allergen-specific immunoglobulin E (IgE) responses in atopic individuals following allergen exposure. CRS represents a multifactorial and heterogeneous disease influenced by anatomical anomalies, genetic predisposition, and environmental exposures. Although conventional therapeutic approaches can mitigate symptoms, they seldom address the underlying mechanisms.

Recent interest has centered on bacterial lysates (BLs) for their immunomodulatory potential. By mimicking pathogen-associated molecular patterns (PAMPs), BLs activate mucosal immunity and restore immune homeostasis, offering promising avenues for the treatment of nasal inflammatory disorders. Accumulating evidence supports their efficacy across in vitro, in vivo, and clinical contexts. Emerging research has identified variability in receptor expression profiles, patterns of eosinophil infiltration, and modulatory roles of organic salts and short-chain fatty acids (SCFAs). In accordance with the Scale for the Assessment of Narrative Review Articles,¹⁴ this narrative review synthesizes recent developments in BL research, constructs a theoretical framework to bridge basic science with clinical application, and outlines future directions to advance innovation in this domain. A comprehensive literature search was conducted through MEDLINE (PubMed) using the Boolean query (“bacterial lysates” OR “OM-85” OR “BV”) AND (“allergic rhinitis” OR “chronic rhinosinusitis”), covering publications from 1 January 1988, to April 1, 2025. Findings were presented in a narrative format aligned with established methodological standards to ensure clarity and coherence.

Composition and preparation of bacterial lysates

BLs are immunomodulatory agents derived from inactivated antigens of common respiratory pathogens,^15,16 including Staphylococcus aureus, Moraxella catarrhalis, Klebsiella pneumoniae, Streptococcus pneumoniae, and Haemophilus influenzae.¹⁷ Designed for the prevention of respiratory tract infections (RTIs) and allergic conditions, BLs are produced through two primary methodologies. Chemical lysis (polyvalent chemical bacterial lysates, PCBLs), which disrupts bacterial membranes under alkaline conditions (pH 11.5–12.5), may compromise protein structure and reduce antigenicity. In contrast, mechanical lysis—used to produce polyvalent mechanical BLs (PMBLs)—employs ultrasonication or high-pressure homogenization to preserve antigenic integrity and enhance immunogenic potential.^18–20 Commercial formulations such as OM-85 BV(Broncho-Vaxom^®) and Liuvac (LW-50020) are chemically lysed preparations. OM-85 comprises 21 bacterial strains from five genera and promotes both cellular and humoral immunity, reinforcing systemic defenses and mucosal barriers while modulating immune responses to deliver synergistic prophylactic and therapeutic effects.^19,21 Liuvac, a composite of BLs,²² stimulates dendritic cell (DC) activation, T and B cell proliferation, IgA secretion, and production of antigen-specific antibodies, while also enhancing cross-protective immunity against unrelated pathogens.²³ Oral administration remains the most common route, typically in the form of sublingual drops, tablets, or capsules.¹⁸ Sublingual delivery is especially effective due to the dense presence of DCs in the sublingual mucosa, ensuring robust immunogenicity and a favorable safety profile.²⁴ BL-induced secretory immunoglobulins form a protective mucosal barrier across the respiratory tract, inhibiting microbial adhesion and neutralizing toxins to strengthen respiratory immunity.²⁵ Evidence supports that sublingual administration elicits durable systemic and mucosal antigen-specific humoral and cellular responses. Notably, it facilitates the generation of antigen-specific memory CD4⁺ T cells, which promote Th1-biased immunity and bolster antimicrobial defense mechanisms.²⁶ Compared to probiotics, BLs offer advantages such as reduced storage requirements, shorter treatment durations, and direct immune stimulation. Unlike vitamin D, which enhances antimicrobial peptide synthesis and inhibits pathogen colonization indirectly,^27,28 BLs exert their effects through active immunostimulation, promoting comprehensive immune balance. Additionally, BLs represent a cost-effective alternative to biologics by combining therapeutic and preventive benefits with a long-term safety profile.^2,29

Immunomodulatory mechanisms of bacterial lysates

Innate immunity (non-specific immunity)

The innate immune response constitutes the primary defense barrier against exogenous insults, involving both hematopoietic and non-hematopoietic tissues. Central effector cells include DCs, neutrophils, eosinophils, macrophages, mast cells, and natural killer (NK) cells, which express a range of pattern recognition receptors (PRRs) to detect pathogens and initiate immune responses.³⁰ BLs potentiate antiviral cytokine secretion, activate macrophages and NK cells, and attenuate eosinophilic infiltration.^31,32 The immune response operates through coordinated multicellular cascades targeting invading pathogens.

Within BLs, lipopolysaccharide binds toll-like receptor 4 (TLR4) on NK cells, inducing IFN-γ release. Human NK cells transcribe multiple TLRs, notably TLR2 and TLR4.^33–37 IFN-γ, via paracrine signaling, activates neighboring macrophages and promotes TNF synthesis. In turn, macrophages engage in autocrine feedback through TNF receptors while simultaneously producing and secreting interleukin-12 (IL-12). The IFN-γ/IL-12 axis provides dual regulation of NK cells by maintaining activation and amplifying IFN-γ output through positive feedback, ultimately enhancing macrophage phagocytic capacity and recruiting neutrophils to infection foci for bactericidal action.^38–42 Notably, BL administration increases circulating NKT and CD4⁺ NKT cell counts relative to baseline, with post-treatment profiles characterized by elevated IFN-γ/IL-4 ratios, increased IL-10 levels, and significantly reduced IL-4 concentrations compared to corticosteroid-treated cohorts.³¹

DCs are indispensable to innate immunity but require maturation to achieve full immunological competency. Maturation pathways empower DCs to regulate innate responses via antiviral cytokine synthesis.

OM-85 BV stimulates bitter taste receptors (T2Rs) in the upper airway epithelium, inducing inducible nitric oxide synthase (iNOS) and consequent nitric oxide (NO) production, a critical component of mucosal defense.^43–45 NO diffuses into the airway surface liquid, enhancing antimicrobial activity, preserving sterility, promoting mucociliary clearance, and increasing ciliary beat frequency, thereby reducing pathogen adherence and facilitating epithelial repair.⁴⁶ Additionally, OM-85 BV augments respiratory burst activity, increasing peroxide and nitrite production and enhancing macrophage-mediated phagocytosis and cytotoxicity.⁴⁷ In vitro evidence demonstrates OM-85 BV induces NO synthesis in murine bone marrow-derived macrophages and promotes NF-κB nuclear translocation via TLR4 signaling. This process is partially dependent on bacterial lipopeptides and muropeptides, corroborating that BLs potentiate macrophage activity through NF-κB pathway activation.⁴⁸

Adaptive immunity (specific immunity)

Adaptive immunity confers broader and more antigen-specific recognition than innate immunity through tightly regulated interactions between antigen-presenting cells (APCs) and T/B lymphocytes, facilitating the development of pathogen-specific effector responses.⁴⁹ DCs, as pivotal APCs, function at the interface of innate and adaptive immunity by initiating antigen-specific activation of T and B cells.^50,51

BLs induce DC activation, enabling antigen processing and presentation to naïve T cells and promoting their polarization into Th1, Th2, Th17, or Treg subsets.⁵¹ Immunomodulatory effects of BLs encompass both innate activation and restoration of Th1/Th2 equilibrium.^22,29 This balance is critical, as Th1 and Th2 lineages exert reciprocal inhibitory effects despite their distinct effector roles.⁵² Th1 polarization is predominantly driven by DC-derived IL-12 and IFN-γ from NK cells, CD4⁺, and CD8⁺ T cells. In turn, Th1-secreted IFN-γ reinforces this axis by suppressing Th2 differentiation via cytokine-mediated feedback loops.⁵¹ Th2 responses, characterized by IL-3, IL-4, IL-5, IL-9, and IL-13 secretion, facilitate eosinophil recruitment and type 2 immunity.⁵³ In murine bronchoalveolar lavage fluid, OM-85 administration increases IFN-γ levels and IFN-γ/IL-4 ratios while concurrently suppressing IL-4, indicating a Th1-skewing effect.⁵⁴ Bidirectional regulation by BLs preserves immune homeostasis in both in vitro and in vivo settings. Clinical data from Kamil Janeczek et al. demonstrate that patients with seasonal AR treated with BLs exhibit stable allergen-specific IgE levels, in contrast to significant IgE elevations in untreated controls.⁵⁵ These results suggest that BLs attenuate Th2-dominant immune responses in seasonal AR. Supporting animal studies further report reductions in Th2 cytokines (IL-4 and IL-13) and IgE, alongside elevations in Th1 cytokines (IFN-γ), indicating that reestablishing immune equilibrium mitigates atopic predisposition, dampens inflammation, and enhances clinical outcomes in allergic conditions.^48,53 Additionally, the study by R-F Han et al. found that IL-10 is a crucial regulatory cytokine for controlling allergic diseases. It directly influences Th2 cells, regulating their survival and the severity of Th2-mediated allergic airway inflammation. Research on asthmatic children revealed a significant increase in serum IL-10 concentration following BL treatment.^31,56

Following oral administration of BLs, PAMPs are recognized by PRRs, including TLRs and other PRRs.⁵⁷ Hanif et al. demonstrated that TLR4 is essential in mice, whereas in humans, a synergistic activation of TLR2 and TLR4 is required. OM-85 activates NF-κB and MAPK signaling pathways via TLR2/4, inducing specific immunoregulatory genes, such as those involved in immune tolerance.⁵⁸ DCs, the most potent APCs, initiate naive T cell activation and proliferation into helper T cell subsets. These DCs migrate to cervical lymph nodes and enter the thoracic duct via lymphatic vessels, where they present antigens and deliver activation signals through TCR, CD28, and CD40L interactions on T cells. Subsequently, CD4⁺ T lymphocytes differentiate into Th1 and Treg subsets, contributing to B cell activation.^53,57 Evidence indicates that PMBL enhances the proportion of activated B lymphocytes expressing surface CD25, suggesting modulation of the IL-2/IL-2R signaling axis—a pivotal pathway for lymphocyte survival, expansion, and differentiation in both humoral and cellular immunity. These findings align with prior in vitro data showing that 24-h PMBL exposure markedly upregulates IL-2Rα expression in human B cells.⁵⁹ Upon activation, B cells differentiate into antibody-secreting plasma cells, initially producing IgM and later undergoing isotype switching to IgA, IgG, or IgE. This class-switch recombination is influenced by the cytokine milieu; IL-4 and IL-13 promote IgE synthesis, whereas IL-10 and IFN-γ favor IgA and IgG production. Given that allergic disorders are associated with elevated IgE levels, the immunoglobulin switching trajectory may either ameliorate or exacerbate allergic manifestations.⁶⁰ Lee et al. reported that BV administration modulates SCFA production, mimicking probiotic activity. These findings reinforce the concept of a unified mucosal immune network, where SCFAs generated in the gut exert immunomodulatory effects on distal tissues via systemic circulation.⁶¹ Additionally, while serum IgG and IgA levels exhibit minimal elevation following oral OM-85-BV intake, significant increases in salivary IgA and IgA within lymph node culture supernatants have been observed. Notably, IgA levels in saliva remained elevated even after immunization with unrelated antigens (e.g. tetanus toxoid), underscoring that OM-85-BV primarily stimulates mucosal immunity—particularly IgA secretion—with limited influence on systemic antibody responses.⁴⁸ Figure 1 summarizes the immune mechanisms of BLs in AR and CRS.

Figure 1.

Main immune mechanisms of bacterial lysates (BLs) in AR and CRS. BLs activate T2R in the upper airways, triggering NOS to release NO, which plays a pivotal role in the innate immune response. BLs also stimulate DCs, which process and present antigens to naïve T cells, promoting their differentiation into Th1, Th2, Th17, or Treg subsets. Th1 differentiation is influenced by DC-derived IL-12 and IFN-γ produced by NK, CD4⁺, and CD8⁺ T cells. Mature Th1 cells secrete IFN-γ, which inhibits Th2 differentiation through cytokine cascades. Th2 cells, in turn, secrete IL-3, IL-4, IL-5, IL-9, and IL-13, orchestrating eosinophil recruitment and type 2 immune responses. Created with BioRender.com. AR: allergic rhinitis; CRS: chronic rhinosinusitis; BL: bacterial lysate; NK: natural killer; IL: interleukin; NO: nitric oxide.

Clinical applications of bacterial lysates (Table 1)

Clinical applications of bacterial lysates in AR

AR is a chronic, non-infectious inflammatory condition of the nasal mucosa, primarily mediated by IgE in individuals with atopy following allergen exposure. Allergen-activated T cells proliferate via the Th2 pathway, secreting cytokines that prompt plasma cells to produce allergen-specific IgE. These antibodies subsequently bind to mast cells and basophils in a process known as “sensitization.”^62,63 Immunotherapies for AR are classified into allergen-specific and non-specific strategies. Due to the limitations of allergen-specific treatments, non-specific therapies—including biologics, microbial agents (e.g. probiotics, BLs), and vitamin D—have gained prominence. BLs, in particular, have garnered increasing attention as a potential treatment for AR.⁶⁴ Commercialized for decades under various brands, BLs exhibit both local and systemic immunomodulatory effects, though their clinical outcomes remain variable.¹⁸

Table 1.

Clinical study of bacterial lysates in the treatment of allergic rhinitis and chronic rhinosinusitis.

Disease	Research/author	Research design	Intervention measures	Main results	Reference (DOI)	Publication year
AR	Meng et al.	Randomized controlled trial (RCT)	BLs (oral, 7 mg capsules daily, 10 consecutive days per month for 3 months)	The treatment significantly reduced the Total Nasal Symptom Score (TNSS), lowered serum IgE levels, and restored the Th1/Th2 balance. IL-4 and IL-13 levels decreased, while IFN-γ levels increased. These therapeutic effects persisted for 4 to 8 weeks.	²⁹	2019
AR	Koatz et al.	Open, prospective, sequential research	BLs combined with standard optimized care (SOC)	Respiratory tract infections (RTIs) were reduced by 45%, accompanied by a 36% decrease in acute exacerbations. Significant increases in both serum and secretory IgA levels were observed.	⁶⁴	2016
AR	Ling et al.	Animal experiment (mice)	BLs long-term intervention	Nasal scratching and sneezing frequency decreased by 78%, nasal eosinophil count reduced by 62%, Th2 cytokines (IL-4, IL-5, IL-13) dropped by 40–55%, and serum-specific IgE levels decreased by 48%.	⁶⁶	2014
AR	Banche et al.	Randomized controlled trial (RCT)	BLs group vs placebo group	Symptoms in 61.5% of patients significantly improved, accompanied by a decrease in IL-4 levels. In the placebo group, only one patient showed improvement.	⁶⁸	2007
CRS	Zagar et al.	Double-blind randomized controlled trial	BLs group vs placebo group (oral 10 days a month for 3 months)	The duration (2.17 days vs. 7.96 days) and frequency (0.38 times vs. 1.09 times) of acute episodes were significantly reduced in the BLs group (p < 0.01).	⁷⁵	1988
CRS	Tao et al.	Randomized controlled trial (RCT)	BLs and Amoxicillin intervention	It demonstrates high safety with minimal side effects, making it a cost-effective adjuvant therapy for CRS.	⁷⁶	2015
CRS	Hong et al.	Prospective cohort study	Treatment of postoperative bacterial lysates	Mucosal repair indices in patients with no nasal polyps (CRSsNP) and low IL-5 expression showed a significant improvement trend.	⁷⁸	2024
CRS	Gómez et al.	Double-blind prospective randomized controlled trial	BLs combined with potassium clavulanate	Children with subacute sinusitis experienced faster symptom improvement, a reduction in the number of infections, and a decreased need for medication.	^7AR4	1998

AR: allergic rhinitis; CRS: chronic rhinosinusitis; BL: bacterial lysate; IgE: immunoglobulin E; IL: interleukin.

Symptom alleviation and immunological biomarker modulation

Several randomized controlled trials (RCTs) have demonstrated that BLs (e.g. OM-85, Broncho-Vaxom) significantly reduce total nasal symptom scores (TNSS), lower serum IgE levels, and restore the Th1/Th2 cytokine balance in patients with AR. A 2019 study by Meng et al. found that OM-85 significantly reduced TNSS compared to placebo, effectively alleviating nasal itching and rhinorrhea. Nasal lavage fluid exhibited decreased IL-4 and IL-13 levels, an increase in IFN-γ, and a reduced IL-4/IFN-γ ratio. Eosinophil counts were also lower, with the benefits of OM-85 lasting 4–8 weeks post-treatment. These results suggest that OM-85 restores Th1/Th2 cytokine balance through cellular and signaling pathways, thereby enhancing mucosal immunity in AR.²⁹ In a separate study, Koatz et al. assessed the efficacy of OM-85 in preventing RTIs and modulating serum/secretory IgA levels in patients with AR, asthma, and COPD. This open-label, prospective sequential study revealed a 74% reduction in RTIs (from 266 to 69) with standard optimized care (SOC), and an additional 45% reduction (to 38) with OM-85 as an adjunctive therapy. Acute exacerbations of underlying diseases decreased by 36% (from 55 to 35) during OM-85 treatment. Immunological analyses revealed significant increases in serum and secretory IgA following OM-85 administration. These findings indicate that OM-85, when added to standard therapy, significantly reduces the incidence of respiratory infections and improves disease control, likely through enhanced mucosal immune responses.⁶⁴ Furthermore, sublingual PMBL tablets effectively alleviate seasonal AR (SAR) symptoms in grass pollen-sensitized children, with Th1-like γδ T cells serving as potential biomarkers for disease severity.⁶⁵

Long-term efficacy and preventive effects

Long-term use of BLs for ≥ 3 months has been shown to reduce the recurrence of AR, especially when used adjunctively with dust mite desensitization therapies. Ling et al. demonstrated that extended OM-85 treatment significantly alleviates AR symptoms, including a 78% reduction in nasal scratching and sneezing (p < 0.01), a 62% decrease in eosinophil infiltration, and a 40–55% reduction in Th2 cytokines (IL-4, IL-5, IL-13) in nasal lavage fluid. Additionally, serum-specific IgE and IgG1 levels were reduced by 48% and 37%, respectively. Histopathological analysis revealed decreased nasal mucosal inflammation (31% compared to controls) and improved goblet cell hyperplasia in OM-85-treated mice. Short-term OM-85 treatment also resulted in a 25–30% reduction in Th2 cytokines and a 22% reduction in IgE, although complete symptom suppression was not achieved. Mechanistically, OM-85 upregulates Foxp3⁺ regulatory T cells in nasal-associated lymphoid tissue and enhances IFN-γ secretion, restoring Th1/Th2 balance. Thus, OM-85 BV controls AR progression via dual, time-dependent immunomodulatory mechanisms, with long-term oral regimens holding promise as preventive strategies.^66,67 Similarly, Banche et al. (2007) conducted an RCT involving 41 patients with AR (26 BL-treated, 15 placebo), assessing clinical and immunological outcomes at baseline (T0) and 3 months post-treatment (T3). BL-treated patients exhibited significant clinical improvements, including a 61.5% improvement in symptoms, a 53.8% reduction in nasal congestion and rhinorrhea, a 50% resolution of ocular symptoms, and a 38.4% improvement in asthma symptoms, with no adverse effects or exacerbations. Efficacy was sustained at the 3-month follow-up, matching T3 outcomes. Immunological analyses indicated selective effects of BL treatment, such as reduced IL-4 (Th2 cytokine) levels, without changes in total IgE, allergen-specific IgE, or IFN-γ levels. In contrast, the placebo group showed minimal improvement, with only one patient reporting partial symptom relief. These results provide mechanistic support for BLs as novel immunomodulatory therapies that can positively influence AR clinical trajectories.⁶⁸ A systematic review and meta-analysis by Li et al. concluded that BL therapy improves symptom control in patients with allergic diseases when combined with conventional treatments, without presenting any adverse risks.⁶⁹

Clinical application of bacterial lysates in the treatment of chronic rhinosinusitis

CRS is a long-term inflammatory condition of the sinus mucosa, persisting for over 12 weeks. CRS leads to physical symptoms such as a diminished sense of smell, rhinorrhea, nasal congestion, and facial/head pain, while also heightening the risk of anxiety and depression. Although not fatal, these persistent symptoms can significantly impact quality of life, work performance, and social function in affected individuals.^70,71 The European consensus document recommends BLs, particularly OM-85BV, for the treatment of adult CRS.⁷² OM-85BV has been used in various countries for decades, with applications in both adults and children for the treatment and prevention of recurrent respiratory infections, including COPD, asthma, and rhinosinusitis. However, it has not yet been FDA-approved in the United States.^44,73

Reduce the number of attacks and surgical needs

BLs reduce the frequency of acute exacerbations in CRS by inhibiting bacterial biofilm formation and pro-inflammatory factors such as IL-6 and TNF-α, potentially allowing some patients to avoid surgical interventions. Gómez et al. conducted a 6-month, double-blind, prospective RCT to assess the safety and efficacy of OM-85 BV in treating subacute sinusitis in children. The experimental and control groups received clavulanate potassium (10 mg/kg daily for 21 days). In addition, the experimental group received OM-85 BV capsules (3.5 mg/day) for 10 days before each month, while the control group received a placebo for 3 months. Results indicated that the experimental group experienced faster symptom improvement and a shorter recovery period. After 6 months of follow-up, the experimental group showed a significant reduction in the number of infections and required less medication compared to the control group. These findings support OM-85 BV's role in accelerating the cure and improvement of subacute sinusitis.⁷⁴ In a separate study, Zagar et al. examined the preventive effect of BLs on CRS recurrence in children. Fifty-one children with acute CRS exacerbations were randomly assigned to receive either OM-85 BV or a placebo under double-blind conditions. Observations and follow-up revealed that BLs significantly reduced both the frequency and duration of CRS recurrences.⁷⁵ Furthermore, Tao et al. demonstrated a coordinated downregulation of SOCS1, SOCS3, TNF-α, and IFN-γ expression in both the OM-85 BV/amoxicillin combination and amoxicillin monotherapy groups compared to model controls, with significant reductions at both mRNA and protein levels. These mechanistic insights validate OM-85 BV's potential as a cost-effective adjunct for CRS management, aligning with previous therapeutic findings.⁷⁶

Combination therapy synergistic effect

Currently, drugs and surgery are the standard treatments for CRS. However, even with medical and surgical interventions, some patients remain prone to frequent relapses and may require secondary surgeries.⁷⁷ When combined with surgical treatment, BLs can offer additional benefits, particularly in improving postoperative endoscopic outcomes. The endotype of CRS has demonstrated clinical value in guiding treatment decisions. Hong et al. aimed to evaluate the efficacy of postoperative BL therapy in patients with different CRS endotypes, conducting a prospective cohort study involving patients who underwent standardized endoscopic sinus surgery. Patients with recurrent upper RTIs and no immune contraindications were included in the treatment group and received periodic BLs post-surgery, while the control group received standard postoperative care. Endoscopic mucosal repair, quality of life, and tissue inflammation were assessed through multiple follow-ups. Although no significant overall difference in efficacy was observed between the two groups, subgroup analysis revealed that mucosal repair in patients with CRS with no nasal polyps (CRSsNP) and low IL-5 expression showed significant improvement.⁷⁸

Conclusion and outlook

BLs exhibit broad immunomodulatory effects by activating both innate and adaptive immune responses. They enhance phagocytic and bactericidal functions through NK cell, macrophage, and neutrophil interactions, while also restoring Th1/Th2 balance through DC-mediated antigen presentation. This process helps reduce IgE levels and suppresses Th2-driven inflammation. Clinical studies indicate that BLs significantly improve the TNSS in patients with AR, reduce Th2 cytokine secretion (IL-4, IL-13), and decrease recurrence rates and the need for surgical interventions in CRS. However, despite substantial evidence supporting the efficacy of BLs, treatment effects can vary. Therefore, further research is essential to explore the underlying mechanisms, the immunogenicity and complexity of BLs, population differences, and more robust evidence on the long-term safety of these treatments. With the continued advancement of immunology and biotechnology, BLs hold the potential to overcome existing treatment limitations and become a key component of the “immune rebalancing” strategy for respiratory diseases, offering a new paradigm that moves beyond symptom control to address the underlying etiology.

Footnotes

Acknowledgment

We would like to thank Chunping Yang for reviewing and providing advice on the final search strategy. We thank Bullet Edits Limited for the linguistic editing and proofreading of the manuscript.

ORCID iDs

Xinyu Huang

Xu Zhang

Mengyuan Liu

Daoming Bai

Rui Yang

Author contributions

XH designed the literature search, collected the data, created the figures, and drafted the initial version of the manuscript with support from CY. XZ offered valuable feedback and revisions to the manuscript. ZZ and ML prepared original draft. DB and RY reviewed and edited the manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by the National Natural Science Foundation of China (No. 82160211) and the Jiangxi Provincial Nature Science Foundation (No. 2021BAG70031).

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

Leth-Møller

Skaaby

Linneberg

. Allergic rhinitis and allergic sensitisation are still increasing among Danish adults. Allergy 2020; 75: 660–668.

Tong

Gao

Deng

, et al. Prevalence of allergic rhinitis and associated risk factors in 6 to 12 years schoolchildren from Wuhan in central China: a cross-sectional study. Am J Rhinol Allergy 2020; 34: 632–641.

Zhou

, et al. Prevalence and risk factors of childhood allergic diseases in eight metropolitan cities in China: a multicenter study. BMC Public Health 2011; 11: 437.

Wang

Zhuang

, et al. Prevalence and risk factors for allergic rhinitis in adults and children living in different grassland regions of Inner Mongolia. Allergy 2020; 75: 234–239.

Sasaki

Morikawa

Yoshida

, et al. The change in the prevalence of wheeze, eczema and rhino-conjunctivitis among Japanese children: findings from 3 nationwide cross-sectional surveys between 2005 and 2015. Allergy 2019; 74: 1572–1575.

Hastan

Fokkens

Bachert

, et al. Chronic rhinosinusitis in Europe–an underestimated disease. A GA²LEN study. Allergy 2011; 66: 1216–1223.

Blackwell

Lucas

Clarke

. Summary health statistics for U.S. adults: national health interview survey, 2012. Vital and Health Statistics Series 10, Data from the National Health Survey 2014: 1–161. 2014/05/14.

Kim

Seong

, et al. Prevalence and risk factors of chronic rhinosinusitis in Korea. Am J Rhinol Allergy 2011; 25: 117–121.

Pilan

Pinna

Bezerra

, et al. Prevalence of chronic rhinosinusitis in Sao Paulo. Rhinology 2012; 50: 129–138.

10.

Shi

Zhang

, et al. Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. Allergy 2015; 70: 533–539.

11.

Avdeeva

Reitsma

Fokkens

. Direct and indirect costs of allergic and non-allergic rhinitis in The Netherlands. Allergy 2020; 75: 2993–2996.

12.

Liu

Chen

Cheng

, et al. Chinese society of allergy and Chinese society of otorhinolaryngology-head and neck surgery guideline for chronic rhinosinusitis. Allergy Asthma Immunol Res 2020; 12: 176–237.

13.

Sánchez Montalvo

Gohy

Rombaux

, et al.

The role of IgA in chronic upper airway disease: friend or foe?

Frontiers in Allergy 2022; 3: 852546.

14.

Baethge

Goldbeck-Wood

Mertens

. SANRA-a scale for the quality assessment of narrative review articles. Res Integrity Peer Rev 2019; 4: 5.

15.

Edwards

Walton

Jackson

, et al. The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations. Allergy 2018; 73: 50–63.

16.

Yin

Zeng

, et al. Broncho-Vaxom in pediatric recurrent respiratory tract infections: a systematic review and meta-analysis. Int Immunopharmacol 2018; 54: 198–209.

17.

Lee

Kim

Lee

, et al. Broncho-Vaxom bacterial lysate prevents asthma via acetate enhancement in mouse model. Pediatr Allergy Immunol: Off Publ Eur Soc Pediatr Allergy Immunol 2023; 34: e14018.

18.

Suárez

Ferrara

Rial

, et al. Bacterial lysates as immunotherapies for respiratory infections: methods of preparation. Front Bioeng Biotechnol 2020; 8: 545.

19.

Jurkiewicz

Zielnik-Jurkiewicz

. Bacterial lysates in the prevention of respiratory tract infections. Otolaryngol Pol 2018; 72: 1–8.

20.

Cazzola

Anapurapu

Page

. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis. Pulm Pharmacol Ther 2012; 25: 62–68.

21.

De Benedetto

Sevieri

. Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art. Multidiscip Respir Med 2013; 8: 33.

22.

Esposito

Soto-Martinez

Feleszko

, et al. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol 2018; 18: 198–209.

23.

Bartkowiak-Emeryk

Emeryk

Roliński

, et al. Impact of polyvalent mechanical bacterial lysate on lymphocyte number and activity in asthmatic children: a randomized controlled trial. Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol 2021; 17: 10.

24.

Cazzola

Capuano

Rogliani

, et al. Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. Curr Opin Pharmacol 2012; 12: 300–308.

25.

Holmgren

Czerkinsky

. Mucosal immunity and vaccines. Nat Med 2005; 11: S45–S53.

26.

Alecsandru

Valor

Sánchez-Ramón

, et al. Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome. Clin Exp Immunol 2011; 164: 100–107.

27.

Chen

Shi

, et al. 1,25-Dihydroxyvitamin D protects intestinal epithelial barrier by regulating the myosin light chain kinase signaling pathway. Inflamm Bowel Dis 2015; 21: 2495–2506.

28.

Zhang

Jin

. 1α,25-Dihydroxyvitamin D3 ameliorates seawater aspiration-induced lung injury by inhibiting the translocation of NF-κB and RhoA. Inflammation 2017; 40: 832–839.

29.

Meng

, et al. Broncho-vaxom alleviates persistent allergic rhinitis in patients by improving Th1/Th2 cytokine balance of nasal mucosa. Rhinology 2019; 57: 451–459.

30.

Kaur

Secord

. Innate immunity. Pediatr Clin N Am 2019; 66: 905–911.

31.

, et al. Bacterial lysate increases the percentage of natural killer T cells in peripheral blood and alleviates asthma in children. Pharmacology 2015; 95: 139–144.

32.

Roth

Block

. Distinct effects of Broncho-Vaxom (OM-85 BV) on gp130 binding cytokines. Thorax 2000; 55: 678–684.

33.

Saikh

Lee

Kissner

, et al. Toll-like receptor and cytokine expression patterns of CD56+ T cells are similar to natural killer cells in response to infection with Venezuelan equine encephalitis virus replicons. J Infect Dis 2003; 188: 1562–1570.

34.

Lauzon

Mian

MacKenzie

, et al. The direct effects of toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell Immunol 2006; 241: 102–112.

35.

Mian

Lauzon

Andrews

, et al. Fimh can directly activate human and murine natural killer cells via TLR4. Mol Ther J Am Soc Gene Ther 2010; 18: 1379–1388.

36.

Chiche

Forel

Thomas

, et al. The role of natural killer cells in sepsis. J Biomed Biotechnol 2011; 2011: 986491.

37.

Kanevskiy

Telford

Sapozhnikov

, et al. Lipopolysaccharide induces IFN-γ production in human NK cells. Front Immunol 2013; 4: 11.

38.

Trinchieri

. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133–146.

39.

Wang

, et al. Nuclear carbonic anhydrase 6B associates with PRMT5 to epigenetically promote IL-12 expression in innate response. Proc Natl Acad Sci U S A 2017; 114: 8620–8625.

40.

Wang

Hui

, et al. Combination of pseudoephedrine and emodin ameliorates LPS-induced acute lung injury by regulating macrophage M1/M2 polarization through the VIP/cAMP/PKA pathway. Chin Med 2022; 17: 19.

41.

Suzuki

Baillo

Albarracin

, et al. Modulation of macrophages TLR4-mediated transcriptional response by Lacticaseibacillus rhamnosus CRL1505 and Lactiplantibacillus plantarum CRL1506. Int J Mol Sci 2025; 26: 2688.

42.

Zhang

Jagannath

. Crosstalk between metabolism and epigenetics during macrophage polarization. Epigenetics Chromatin 2025; 18: 16.

43.

Workman

Maina

Brooks

, et al. The role of quinine-responsive taste receptor family 2 in airway immune defense and chronic rhinosinusitis. Front Immunol 2018; 9: 624.

44.

Triantafillou

Workman

Patel

, et al. Broncho-Vaxom® (OM-85 BV) soluble components stimulate sinonasal innate immunity. Int Forum Allergy Rhinol 2019; 9: 370–377.

45.

Marseglia

Benazzo

Biasci

, et al. OM-85 in the prevention of respiratory infections: state-of-the-art and future perspectives in clinical practice. J Biol Regul Homeost Agents 2021; 35: 847–863.

46.

Cardinale

Lombardi

Rossi

, et al. Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85. Expert Rev Respir Med 2020; 14: 1019–1026.

47.

Mauel

Van Pham

Kreis

, et al. Stimulation by a bacterial extract (Broncho-Vaxom) of the metabolic and functional activities of murine macrophages. Int J Immunopharmacol 1989; 11: 637–645.

48.

Huber

Mossmann

Bessler

. Th1-orientated immunological properties of the bacterial extract OM-85-BV. Eur J Med Res 2005; 10: 209–217.

49.

Bonilla

Oettgen

. Adaptive immunity. J Allergy Clin Immunol 2010; 125: S33–S40.

50.

Roy

Rizvi

Awasthi

. Metabolic checkpoints in differentiation of helper T cells in tissue inflammation. Front Immunol 2018; 9: 3036.

51.

Butcher

Zhu

. Recent advances in understanding the Th1/Th2 effector choice. Fac Rev 2021; 10: 30.

52.

Larché

Kay

. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003; 111: 450–463.

53.

Kaczynska

Klosinska

Janeczek

, et al. Promising immunomodulatory effects of bacterial lysates in allergic diseases. Front Immunol 2022; 13: 907149.

54.

, et al. OM85 Ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting notch expression and modulating the IFN-γ/IL-4 ratio. Sci Rep 2025; 15: 5436.

55.

Janeczek

Emeryk

Rachel

, et al. Polyvalent mechanical bacterial lysate administration improves the clinical course of grass pollen-induced allergic rhinitis in children: a randomized controlled trial. J Allergy Clin Immunol Pract 2021; 9: 453–462.

56.

Han

Wang

, et al. Study on clinical effect and immunologic mechanism of infants capillary bronchitis secondary bronchial asthma treated with bacterial lysates Broncho-Vaxom. Eur Rev Med Pharmacol Sci 2016; 20: 2151–2155.

57.

Macri

Fancke

Radford

, et al. Monitoring dendritic cell activation and maturation. Methods in Molecular Biology (Clifton, NJ) 2019; 1988: 403–418.

58.

Khameneh

Bolis

Ventura

PMO

, et al. The bacterial lysate OM-85 engages toll-like receptors 2 and 4 triggering an immunomodulatory gene signature in human myeloid cells. Mucosal Immunol 2024; 17: 346–358.

59.

Lanzilli

Falchetti

Cottarelli

, et al. In vivo effect of an immunostimulating bacterial lysate on human B lymphocytes. Int J Immunopathol Pharmacol 2006; 19: 551–559.

60.

Lambrecht

Hammad

Fahy

. The cytokines of asthma. Immunity 2019; 50: 975–991.

61.

van der

Wells

. Microbial regulation of host physiology by short-chain fatty acids. Trends Microbiol 2021; 29: 700–712.

62.

Qiu

Zhong

Huang

, et al. Cell-bound IgE and plasma IgE as a combined clinical diagnostic indicator for allergic patients. Sci Rep 2020; 10: 4700.

63.

Hsin

Hew

Aui

, et al. A single multiplex CytoBas assay incorporating eight major components for accurate detection of allergen sensitization in asthma and allergic rhinitis. Allergy 2025; 80: 1047–1059.

64.

Koatz

Coe

Cicerán

, et al. Clinical and immunological benefits of OM-85 bacterial lysate in patients with allergic rhinitis, asthma, and COPD and recurrent respiratory infections. Lung 2016; 194: 687–697.

65.

Janeczek

Kowalska

Zarobkiewicz

, et al. Effect of immunostimulation with bacterial lysate on the clinical course of allergic rhinitis and the level of γδT, iNKT and cytotoxic T cells in children sensitized to grass pollen allergens: a randomized controlled trial. Front Immunol 2023; 14: 1073788.

66.

Han

Zheng

Sun

, et al. A bacterial extract of OM-85 Broncho-Vaxom prevents allergic rhinitis in mice. Am J Rhinol Allergy 2014; 28: 110–116.

67.

Zhu

Wang

Feng

, et al. Oral bacterial lysate OM-85: advances in pharmacology and therapeutics. Drug Des Devel Ther 2024; 18: 4387–4399.

68.

Banche

Allizond

Mandras

, et al. Improvement of clinical response in allergic rhinitis patients treated with an oral immunostimulating bacterial lysate: in vivo immunological effects. Int J Immunopathol Pharmacol 2007; 20: 129–138.

69.

Zhou

Zhang

, et al. Bacterial lysate treatment in allergic disease: a systematic review and meta-analysis. Pediatr Allergy Immunol: Off Publ Eur Soc Pediatr Allergy Immunol 2021; 32: 1813–1823.

70.

Kim

, et al. Association of chronic rhinosinusitis with depression and anxiety in a nationwide insurance population. JAMA Otolaryngology– Head Neck Surg 2019; 145: 313–319.

71.

Khan

Gajula

Goehring

, et al. Chronic rhinosinusitis and mental health. JAMA Otolaryngology– Head Neck Surg 2024; 150: 943–951.

72.

Fokkens

Lund

Hopkins

, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 2020; 58: 1–464.

73.

Yao

Qin

Song

, et al. Bacterial lysate add-on therapy in adult and childhood asthma: a systematic review and meta-analysis. J Thorac Dis 2023; 15: 3143–3157.

74.

Gómez Barreto

De la Torre

Alvarez

, et al. Safety and efficacy of OM-85-BV plus amoxicillin/clavulanate in the treatment of subacute sinusitis and the prevention of recurrent infections in children. Allergol Immunopathol (Madr) 1998; 26: 17–22.

75.

Zagar

Löfler-Badzek

. Broncho-Vaxom in children with rhinosinusitis: a double-blind clinical trial. ORL J Otorhinolaryngol Relat Spec 1988; 50: 397–404.

76.

Tao

Yuan

, et al. Bacterial extract OM-85 BV protects mice against experimental chronic rhinosinusitis. Int J Clin Exp Pathol 2015; 8: 6800–6806.

77.

Feleszko

Rossi

Krenke

, et al. Immunoactive preparations and regulatory responses in the respiratory tract: potential for clinical application in chronic inflammatory airway diseases. Expert Rev Respir Med 2020; 14: 603–619.

78.

Hong

Yang

Kim

, et al. Endotype and phenotype related postoperative effects of bacterial lysate in chronic rhinosinusitis. Ann Otol Rhinol Laryngol 2024; 133: 805–813.

Bacterial lysates in allergic rhinitis and chronic rhinosinusitis: Mechanisms and clinical evidence

Abstract

Keywords

Introduction

Composition and preparation of bacterial lysates

Immunomodulatory mechanisms of bacterial lysates

Innate immunity (non-specific immunity)

Adaptive immunity (specific immunity)

Clinical applications of bacterial lysates (Table 1)

Clinical applications of bacterial lysates in AR

Symptom alleviation and immunological biomarker modulation

Long-term efficacy and preventive effects

Clinical application of bacterial lysates in the treatment of chronic rhinosinusitis

Reduce the number of attacks and surgical needs

Combination therapy synergistic effect

Conclusion and outlook

Footnotes

Acknowledgment

ORCID iDs

Author contributions

Funding

Declaration of conflicting interests

References